{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:23:10Z","timestamp":1778620990453,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"This study was funded by Novartis (Taiwan) Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12325-021-01893-6","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T08:02:46Z","timestamp":1631260966000},"page":"5286-5301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of the 10 cm2 Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer\u2019s Dementia: A 48-Week Real-World Observational Study"],"prefix":"10.1007","volume":"38","author":[{"given":"Chiung-Chih","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsi-Hsien","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Wan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ta-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-I.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4900-5967","authenticated-orcid":false,"given":"Chaur-Jong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"1893_CR1","unstructured":"World Alzheimer Report 2019. Alzheimer\u2019s disease international: attitudes to dementia. https:\/\/www.alz.co.uk\/research\/WorldAlzheimerReport2019.pdf. Accessed 16 Dec 2019."},{"key":"1893_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/1533317513504818","volume":"29","author":"WF Wang","year":"2014","unstructured":"Wang WF, Chiu PY, Lin YT, Hu CJ, Fuh JL, Yang YH. Registration of Alzheimer\u2019s disease in Taiwan: patient and informant. Am J Alzheimers Dis Other Demen. 2014;29:18\u201322.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"1893_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139154","volume":"10","author":"LY Fan","year":"2015","unstructured":"Fan LY, Sun Y, Lee HJ, Yang SC, Chen TF, Lin KN, et al. Marital status, lifestyle and dementia: a nationwide survey in Taiwan. PLoS\u00a0ONE. 2015;10: e0139154.","journal-title":"PLoS\u00a0ONE"},{"key":"1893_CR4","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s12325-019-00939-0","volume":"36","author":"CC Chang","year":"2019","unstructured":"Chang CC, Peng GS, Lai TJ, Li CH, Liu CK. A 48-week, multicenter, open-label, observational study evaluating oral rivastigmine in patients with mild-to-moderate Alzheimer\u2019s disease in Taiwan. Adv Ther. 2019;36:1455\u201364.","journal-title":"Adv Ther"},{"issue":"4 Suppl 1","key":"1893_CR5","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1212\/01.wnl.0000281847.17519.e0","volume":"69","author":"B Winblad","year":"2007","unstructured":"Winblad B, Grossberg G, Fr\u00f6lich L, Farlow M, Zechner S, Nagel J, et al. IDEAL: a 6-month, double-blind, placebo controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14-22.","journal-title":"Neurology"},{"key":"1893_CR6","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.14r01654","author":"CH Sadowsky","year":"2014","unstructured":"Sadowsky CH, Micca JL, Grossberg GT, Velting DM. Rivastigmine from capsules to patch: Therapeutic advances in the management of Alzheimer\u2019s disease and Parkinson\u2019s disease dementia. Prim Care Companion CNS Disord. 2014. https:\/\/doi.org\/10.4088\/PCC.14r01654.","journal-title":"Prim Care Companion CNS Disord."},{"key":"1893_CR7","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1185\/03007991003688888","volume":"26","author":"S Gauthier","year":"2010","unstructured":"Gauthier S, Juby A, Dalziel W, R\u00e9hel B. Schecter R and on behalf of the EXPLORE investigators. Effects of rivastigmine on common symptomatology of Alzheimer\u2019s disease (EXPLORE). Curr Med Res Opin. 2010;26:1149\u201360.","journal-title":"Curr Med Res Opin"},{"key":"1893_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3233\/JAD-2010-101185","volume":"22","author":"MN Sabbagh","year":"2010","unstructured":"Sabbagh MN, Malek-Ahmadia M, Kataria R, Beldena CM, Connor DJ, Pearson C, et al. The Alzheimer\u2019s questionnaire: a proof of concept study for a new informant-based dementia assessment. J Alzheimers Dis. 2010;22:1015\u201321.","journal-title":"J Alzheimers Dis"},{"key":"1893_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1017\/S1041610294001602","volume":"6","author":"EL Teng","year":"1994","unstructured":"Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, et al. The cognitive abilities screening instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr. 1994;6:45\u201358.","journal-title":"Int Psychogeriatr"},{"key":"1893_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.2174\/1567205014666171010112518","volume":"15","author":"YH Yang","year":"2018","unstructured":"Yang YH, Wu MN, Chou PS, Su HC, Lin SH, Sung PS. Longitudinal neuropsychological outcome in Taiwanese Alzheimer\u2019s disease patients treated with medication. Curr Alzheimer Res. 2018;15:474\u201381.","journal-title":"Curr Alzheimer Res"},{"key":"1893_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4088\/PCC.v09n0205","volume":"9","author":"DS Geldmacher","year":"2007","unstructured":"Geldmacher DS. Treatment guidelines for Alzheimer\u2019s disease: redefining perceptions in primary care. Prim Care Companion J Clin Psychiatry. 2007;9:113\u201321.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"1893_CR12","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1185\/030079907X233403","volume":"23","author":"G Small","year":"2007","unstructured":"Small G, Dubois B. A review of compliance to treatment in Alzheimer\u2019s disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007;23:2705\u201313.","journal-title":"Curr Med Res Opin"},{"key":"1893_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.trci.2018.06.013","volume":"5","author":"CJ Chang","year":"2019","unstructured":"Chang CJ, Chou TC, Chang CC, Chen TF, Hu CJ, Fuh JL, et al. Persistence and adherence to rivastigmine in patients with dementia: results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan. Alzheimers Dement (N Y). 2019;5:46\u201351.","journal-title":"Alzheimers Dement (N Y)"},{"key":"1893_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"1893_CR15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3233\/JAD-2012-120109","volume":"31","author":"MC Chou","year":"2012","unstructured":"Chou MC, Chen CH, Liu CK, Chen SH, Wu SJ, Yang YH. Concentrations of rivastigmine and NAP 226\u201390 and the cognitive response in Taiwanese Alzheimer\u2019s disease patients. J Alzheimers Dis. 2012;31:857\u201364.","journal-title":"J Alzheimers Dis"},{"key":"1893_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/gps.1788","volume":"22","author":"B Winbald","year":"2007","unstructured":"Winbald B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer\u2019s disease\u2013\u2013rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22:456\u201367.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1893_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1742-1241.2009.02052.x","volume":"63","author":"A Kurz","year":"2009","unstructured":"Kurz A, Farlow M, Lefe\u2019vre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer\u2019s disease: a review. Int J Clin Pract. 2009;63:799\u2013805.","journal-title":"Int J Clin Pract"},{"key":"1893_CR18","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00213-018-5135-x","volume":"236","author":"PS Chou","year":"2019","unstructured":"Chou PS, Jhang KM, Huang LC, Wang WF, Yang YH. Skinfold thickness for rivastigmine patch application in Alzheimer\u2019s disease. Psychopharmacology. 2019;236:1255\u201360.","journal-title":"Psychopharmacology"},{"key":"1893_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000017231","volume":"11","author":"O Aevarsson","year":"2000","unstructured":"Aevarsson O, Skoog I. A longitudinal population study of the mini-mental state examination in the very old: relation to dementia and education. Dement Geriatr Cogn Disord. 2000;11:166\u201375.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1893_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1185\/03007995.2013.802230","volume":"29","author":"S Gauthier","year":"2013","unstructured":"Gauthier S, Robillard A, Cohen S, Black S, Sampalis J, Colizza D, et al. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer\u2019s disease: the EMBRACE study. Curr Med Res Opin. 2013;29:989\u20131000.","journal-title":"Curr Med Res Opin"},{"key":"1893_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1600-0404.2008.01086.x","volume":"119","author":"L Minthon","year":"2009","unstructured":"Minthon L, Wallin AK, Eriksson S, Wattmo C, Andreasen N. Long-term rivastigmine treatment in a routine clinical setting. Acta Neurol Scand. 2009;119:180\u20135.","journal-title":"Acta Neurol Scand"},{"key":"1893_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10072-014-2002-3","volume":"36","author":"A Cagnin","year":"2015","unstructured":"Cagnin A, Cester A, Costa B, Ermani M, Gabelli C, Gambina G, et al. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer\u2019s disease. Neurol Sci. 2015;36:457\u201363.","journal-title":"Neurol Sci"},{"key":"1893_CR23","first-page":"383","volume":"10","author":"TH Lai","year":"2016","unstructured":"Lai TH, Wang WF, Yip BS, Yang YW, Peng GS, Tsai SJ, et al. Real-world evaluation of compliance and preference in Alzheimer\u2019s disease treatment: an observational study in Taiwan. Patient Prefer Adherence. 2016;10:383\u201390.","journal-title":"Patient Prefer Adherence"},{"key":"1893_CR24","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","volume":"318","author":"M R\u00f6sler","year":"1999","unstructured":"R\u00f6sler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal\u00adBianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial. BMJ. 1999;318:633\u20138.","journal-title":"BMJ"},{"key":"1893_CR25","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1742-1241.2011.02713.x","volume":"65","author":"K Articus","year":"2011","unstructured":"Articus K, Baier M, Tracik F, K\u00fchn F, Preu\u00df UW, Kurz A. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer\u2019s disease. Int J Clin Pract. 2011;65:790\u20136.","journal-title":"Int J Clin Pract"},{"key":"1893_CR26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1185\/030079903125002450","volume":"19","author":"S Gauthier","year":"2003","unstructured":"Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer\u2019s disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19:707\u201314.","journal-title":"Curr Med Res Opin"},{"key":"1893_CR27","unstructured":"Exelon patch\u00ae. US prescribing information. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/exelonpatch.pdf. Accessed 30 Oct 2019."},{"key":"1893_CR28","unstructured":"Exelon\u00ae for oral use. US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020823s036,021025s024lbl.pdf. Accessed 30 Aug 2021."},{"key":"1893_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0020-7489(99)00003-6","volume":"36","author":"AA Ryan","year":"1999","unstructured":"Ryan AA. Medication compliance and older people: a review of the literature. Int J Nurs Stud. 1999;36:153\u201362.","journal-title":"Int J Nurs Stud"},{"key":"1893_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1368-5031.2005.00769.x","volume":"60","author":"T Dantoine","year":"2006","unstructured":"Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer\u2019s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract. 2006;60:110\u20138.","journal-title":"Int J Clin Pract"},{"key":"1893_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1185\/030079902125000471","volume":"18","author":"S Auriacombe","year":"2002","unstructured":"Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety of Rivastigmine in patients with Alzheimer\u2019s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002;18:129\u201338.","journal-title":"Curr Med Res Opin"},{"key":"1893_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/1533317509333037","volume":"24","author":"CH Sadowsky","year":"2009","unstructured":"Sadowsky CH, Dengiz A, Olin JT, Koumaras B, Meng X, Brannan S. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen. 2009;24:267\u201375.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"1893_CR33","first-page":"PCC.09m00852","volume":"12","author":"CH Sadowsky","year":"2010","unstructured":"Sadowsky CH, Dengiz A, Meng X, Olin JT. Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer\u2019s disease: 20-week extension phase results. Prim Care Companion J Clin Psychiatry. 2010;12:PCC.09m00852.","journal-title":"Prim Care Companion J Clin Psychiatry."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01893-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01893-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01893-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T09:04:39Z","timestamp":1632819879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01893-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1893"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01893-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]},"assertion":[{"value":"27 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}